Navigation Links
Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Date:10/7/2008

VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - Burcon NutraScience Corporation (TSX-V: BU) announced today that its Puratein(R) and Supertein(TM) canola protein isolates are GRAS (Generally Recognized As Safe) for their intended use in a variety of food and beverage applications. The products have been self-affirmed GRAS through an independent evaluation by a panel of qualified experts in the fields of food safety, toxicology, nutritional sciences, food allergies and pediatric nutrition. Burcon's Puratein(R) and Supertein(TM) are the first canola protein isolates to have attained GRAS status in the United States. GRAS status permits Puratein(R) and Supertein(TM) to be marketed and used in a variety of mainstream foods and beverages for human consumption.

Puratein(R) and Supertein(TM) are expected to participate with soy, dairy and egg proteins in the multi-billion dollar global protein ingredient market. Protein ingredients are valued for both their nutritional qualities as well as their functional applications in foods and beverages.

Puratein(R) is a canola protein isolate with functional properties that include emulsification, gel formation, thickening, formation of heat-stable foams, and water- and ingredient-binding. Applications for Puratein(R) include dressings, meat substitutes, baked goods and protein bars, among many others.

Supertein(TM) is a canola protein isolate with functional properties including excellent solubility, the ability to form transparent solutions and foaming. Applications for Supertein(TM) include beverages, confectionery, aerated desserts, and protein bars, among many others. Nutritionally, the proteins are equally exciting with unique amino acid profiles.

"Achieving GRAS status is a major advancement in the commercialization of Puratein(R) and Supertein(TM), the world's first food-grade canola proteins," stated Johann F. Tergesen, Burcon's President & COO who added, "We benefited from the expertise of our
'/>"/>

SOURCE Burcon NutraScience Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
2. Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection
3. Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
4. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
5. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
6. The Childrens Hospital of Philadelphia Announces New Regional Participant in The National Childrens Study
7. Lilly Announces Initiation of Second Global Phase III Trial of Investigational Alzheimers Disease Compound
8. Resurgent Health and Medical Announces That Childrens Hospitals and Clinics of Minnesota has Ordered 25 CleanTech Automated Handwashing Systems
9. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
10. Evalve Announces Enrollment Completion of the EVEREST Randomized Study
11. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Research Future published a Half Cooked Research Report on Endoscopy Devices ... 33.6 million during the period 2016 to 2022 from USD 28.7 ... ... examined as a swiftly growing market and expected to grow at ... in various regions.  The increasing growth in endoscopy procedures is influencing ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. ... (CHNC) has selected Velos and its flagship technology ... and multicenter initiatives. CHNC is a ... Neonatal Intensive Care Units at leading children,s hospitals ... consortium provides a benchmark of care and short-term ...
(Date:1/17/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is ... Inc. ("Anthera" or the "Company") (NASDAQ: ANTH ). ... the investigation by visiting the firm,s site: www.bgandg.com/anth .   ... its officers and/or directors have violated Sections 10(b) and 20(a) ... ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will ... of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention ... long been the gold standard for high-definition, in-ear earphones. This classic earphone has ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
Breaking Medicine News(10 mins):